Effect of N-acetylcysteine and/or deferoxamine on oxidative stress and hyperactivity in an animal model of mania

[1]  Flávio Kapczinski,et al.  The role of hippocampus in the pathophysiology of bipolar disorder , 2007, Behavioural pharmacology.

[2]  Junxia Xie,et al.  Neuroprotective effects of iron chelator Desferal on dopaminergic neurons in the substantia nigra of rats with iron-overload , 2006, Neurochemistry International.

[3]  C. Jang,et al.  Effect of α-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity , 2006, Brain Research.

[4]  B. Frey,et al.  Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. , 2006, Journal of psychiatry & neuroscience : JPN.

[5]  J. Azorin,et al.  Les anomalies structurales observées en imagerie cérébrale dans le trouble bipolaire , 2006 .

[6]  B. Frey,et al.  Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. , 2006, Life sciences.

[7]  B. Frey,et al.  Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania. , 2006, Bipolar disorders.

[8]  B. Frey,et al.  Changes in Antioxidant Defense Enzymes after d-amphetamine Exposure: Implications as an Animal Model of Mania , 2006, Neurochemical Research.

[9]  M. Andrades,et al.  Effects of N-acetylcysteine plus deferoxamine in lipopolysaccharide-induced acute lung injury in the rat* , 2006, Critical care medicine.

[10]  F. Wan,et al.  Effects of α-phenyl-N-tert-butyl nitrone and N-acetylcysteine on hydroxyl radical formation and dopamine depletion in the rat striatum produced by d-amphetamine , 2006, European Neuropsychopharmacology.

[11]  D. Ferriero,et al.  Hypoxia-inducible factor 1α and erythropoietin upregulation with deferoxamine salvage after neonatal stroke , 2005, Experimental Neurology.

[12]  J. Quevedo,et al.  Protective effect of N-acetylcysteine and deferoxamine on carbon tetrachloride-induced acute hepatic failure in rats , 2004, Critical care medicine.

[13]  K. Hashimoto,et al.  Effect of antioxidant N-acetyl-l-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine , 2004, Brain Research.

[14]  J. Soares,et al.  Perspectives for the development of animal models of bipolar disorder , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[15]  Michael E. Andrades,et al.  Treatment with N-acetylcysteine plus deferoxamine protects rats against oxidative stress and improves survival in sepsis* , 2004, Critical care medicine.

[16]  J. Cadet,et al.  Speed kills : cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis , 2003 .

[17]  T. Jay.  Dopamine: a potential substrate for synaptic plasticity and memory mechanisms , 2003, Progress in Neurobiology.

[18]  S. Haber,et al.  Imaging Human Mesolimbic Dopamine Transmission with Positron Emission Tomography. Part II: Amphetamine-Induced Dopamine Release in the Functional Subdivisions of the Striatum , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[19]  H. Canatan,et al.  Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder , 2002, Cell biochemistry and function.

[20]  U. Dirnagl,et al.  Desferrioxamine Induces Delayed Tolerance against Cerebral Ischemia in Vivo and in Vitro , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[21]  M. Mora,et al.  Antioxidant and Pro-oxidant Effect of the Thiolic Compounds N -acetyl- l -cysteine and Glutathione against Free Radical-induced Lipid Peroxidation , 2002, Free radical research.

[22]  R. Belmaker,et al.  Transcranial magnetic stimulation in an amphetamine hyperactivity model of mania. , 2001, Bipolar disorders.

[23]  I. Izquierdo,et al.  Pharmacological differences between memory consolidation of habituation to an open field and inhibitory avoidance learning. , 2001, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[24]  R. Keith,et al.  Differential sensitivity to lithium's reversal of amphetamine-induced open-field activity in two inbred strains of mice , 2001, Behavioural Brain Research.

[25]  V. Kagan,et al.  Interaction between 6-hydroxydopamine and transferrin: "Let my iron go". , 2000, Biochemistry.

[26]  K. Vrana,et al.  Cytotoxic and genotoxic potential of dopamine , 1999, Journal of neuroscience research.

[27]  M. LaVoie,et al.  Dopamine Quinone Formation and Protein Modification Associated with the Striatal Neurotoxicity of Methamphetamine: Evidence against a Role for Extracellular Dopamine , 1999, The Journal of Neuroscience.

[28]  B. Yamamoto,et al.  The effects of methamphetamine on the production of free radicals and oxidative stress. , 1998, The Journal of pharmacology and experimental therapeutics.

[29]  B Kolb,et al.  Persistent Structural Modifications in Nucleus Accumbens and Prefrontal Cortex Neurons Produced by Previous Experience with Amphetamine , 1997, The Journal of Neuroscience.

[30]  D. Duval,et al.  Role of glutathione metabolism in the glutamate-induced programmed cell death of neuronal-like PC12 cells. , 1997, European journal of pharmacology.

[31]  J. Lisman,et al.  D1/D5 Dopamine Receptor Activation Increases the Magnitude of Early Long-Term Potentiation at CA1 Hippocampal Synapses , 1996, The Journal of Neuroscience.

[32]  R. Post,et al.  A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures , 1996, Molecular Neurobiology.

[33]  P. Goldman-Rakic,et al.  Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[34]  U. McCann,et al.  Neurotoxic Amphetamine Analogues: Effects in Monkeys and Implications for Humans a , 1992, Annals of the New York Academy of Sciences.

[35]  S. De Flora,et al.  Antioxidant activity and other mechanisms of thiols involved in chemoprevention of mutation and cancer. , 1991, The American journal of medicine.

[36]  B. Berger,et al.  Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates , 1991, Trends in Neurosciences.

[37]  B. Halliwell.  Oxidants and human disease: some new concepts 1 , 1987, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  D. J. Reed,et al.  Glutathione depletion and susceptibility. , 1984, Pharmacological reviews.

[39]  L. Seiden,et al.  Increased dopamine metabolism in the rat neostriatum after toxic doses of d-methylamphetamine , 1983, Neuropharmacology.

[40]  C. Rutledge,et al.  Effects of the d- and l-isomers of amphetamine on uptake, release and catabolism of norepinephrine, dopamine and 5-hydroxytryptamine in several regions of rat brain. , 1976, Biochemical pharmacology.

[41]  C. Mytilineou,et al.  Amphetamine: evaluation of d- and l-isomers as releasing agents and uptake inhibitors for 3H-dopamine and 3H-norepinephrine in slices of rat neostriatum and cerebral cortex. , 1975, The Journal of pharmacology and experimental therapeutics.

[42]  R. Baldessarini,et al.  Uptake of (3H)-catecholamines by homogenates of rat corpus striatum and cerebral cortex: effects of amphetamine analogues. , 1973, Neuropharmacology.

[43]  R. Ferris,et al.  A comparison of the capacities of isomers of amphetamine, deoxypipradrol and methylphenidate to inhibit the uptake of tritiated catecholamines into rat cerebral cortex slices, synaptosomal preparations of rat cerebral cortex, hypothalamus and striatum and into adrenergic nerves of rabbit aorta. , 1972, The Journal of pharmacology and experimental therapeutics.

[44]  S. Snyder,et al.  Catecholamine uptake by synaptosomes in homogenates of rat brain: stereospecificity in different areas. , 1969, The Journal of pharmacology and experimental therapeutics.

[45]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[46]  Ikuko Miyazaki,et al.  Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease , 2009, Neurotoxicity Research.

[47]  V. V. Solov'ev,et al.  Prooxidant and cytotoxic action of N-acetylcysteine and glutathione in combinations with vitamin B12b , 2007, Cell and Tissue Biology.

[48]  I. Kopin.  The pharmacology of Parkinson's disease therapy: an update. , 1993, Annual review of pharmacology and toxicology.

[49]  C. Olanow,et al.  An introduction to the free radical hypothesis in Parkinson's disease , 1992, Annals of neurology.

[50]  E. Stadtman,et al.  Determination of carbonyl content in oxidatively modified proteins. , 1990, Methods in enzymology.

[51]  O. Aruoma,et al.  The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. , 1989, Free radical biology & medicine.

[52]  B. Halliwell,et al.  Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action? , 1989, Free radical biology & medicine.